Laser for Vulvar Lichen Sclerosus: Four Evidence Checks

If laser is proposed for diagnosed vulvar lichen sclerosus, ask what it is expected to change: burning, itching, pain, the appearance of the skin or the longer-term course of the condition. The evidence needs to match that goal.

The newer trial measured symptoms at three months

The 2026 open-label trial¹ randomized 245 women to three CO2 laser sessions or tapered clobetasol propionate 0.05% for three months. Its main outcome was the 0–30 burn-itch-pain score.¹

Median improvement was eight points with laser versus five with clobetasol. The adjusted between-group estimate favored laser by 2.90 points, with a 95% confidence interval of 1.15–4.64 points.¹

Those are symptom-score changes, not percentages cured.¹

The later crossover did not preserve random assignment

After the primary assessment, participants could choose the alternative treatment. Additional improvement among those switching from clobetasol to laser was exploratory, rather than a randomized test of a sequential-treatment strategy. The initial comparison was unblinded and lacked sham procedures.¹

Ask which evidence supports your proposed treatment sequence.

The sham-controlled trial examined tissue as well as symptoms

A 2021 trial² randomized 40 women with biopsy-confirmed active disease to five laser or sham treatments over 24 weeks. 37 had posttreatment biopsy data. Participants, treating clinicians and the pathologist were masked to assignment.²

It found no significant between-group improvement in the primary histopathology outcome, meaning changes assessed under the microscope. Patient-reported symptoms improved in both groups, without a significant difference between them.²

The El.En Group supplied funding and the laser; the Gynecologic Cancer Research Foundation also contributed funding.²

The protocols and primary outcomes differed; these were not identical treatment comparisons.¹²

Current guidance keeps the ongoing care plan in view

The S3 guideline published in March 2026 for German-speaking countries recommends potent or ultrapotent topical corticosteroids, alongside emollient care, for women with genital lichen sclerosus. It says fractional ablative CO2 laser may be considered, an open recommendation, rather than a strong recommendation to use it.³

It recommends follow-up initially, for example, every 3–6 months, then about every 12 months when stable. Review includes symptom control, skin color and texture, urinary, bowel and sexual difficulties, and monitoring for precancerous or cancerous changes. Adults not responding to potent topical steroids should receive specialist follow-up.³

For a laser consultation, ask what happens to your ointment prescription, who checks the skin afterward and how maintenance will be arranged.

Bring the prescription and symptom history

“The Itch That Isn’t Yeast” in Down There, Decoded discusses lichen sclerosus, prescribed steroid treatment and continuing skin checks. Bring your current instructions and dated notes about burning, itching, pain and visible changes. Our lichen sclerosus follow-up guide helps organize that review.